Tumor angiogenesis as an early marker of long-term prostate cancer mortality

Future Oncology

Volumn 6, Issue 3, 2010, Pages 341-345

  Zhu, Wenhui ^a   Dahut, William L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Microvessel density; Prostate cancer; Prostate cancer specific mortality

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ANGIOGENESIS; BONE METASTASIS; CANCER MORTALITY; CLINICAL FEATURE; CONTROLLED STUDY; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NOTE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; TUMOR VASCULARIZATION;

EID: 77949477546     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.177     Document Type: Note

References (38)

1. Mucci LA, Powolny A, Giovannucci E et al.: Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J. Clin. Oncol. 27(33), 5627-5633 (2009).
2. Catalona WJ, Smith DS, Ratliff TL et al.: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270(8), 948-954 (1993).
3. Roehl KA, Han M, Ramos CG et al.: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J. Urol. 172(3), 910-914 (2004).
4. Andriole GL, Crawford ED, Grubb RL 3rd et al.: Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360(13), 1310-1319 (2009).
5. Schroder FH, Hugosson J, Roobol MJ et al.: Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360(13), 1320-1328 (2009).
6. Haas GP, Delongchamps N, Brawley OW et al.: The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can. J. Urol. 15(1), 3866-3871 (2008).
7. Shariat SF, Karakiewicz PI, Margulis V et al.: Inventory of prostate cancer predictive tools. Curr. Opin. Urol. 18(3), 279-296 (2008).
8. D'Amico AV, Whittington R, Malkowicz SB et al.: Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95(2), 281-286 (2002).
9. D'Amico AV, Whittington R, Malkowicz SB et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11), 969-974 (1998).
10. Makarov DV, Trock BJ, Humphreys EB et al.: Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69(6), 1095-1101 (2007).
11. Kattan MW, Potters L, Blasko JC et al.: Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 58(3), 393-399 (2001).
12. Potters L, Morgenstern C, Calugaru E et al.: 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J. Urol. 179(5 Suppl.), S20-S24 (2008).
13. Stephenson AJ, Scardino PT, Eastham JA et al.: Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J. Natl Cancer Inst. 98(10), 715-717 (2006).
14. Zelefsky MJ, Kattan MW, Fearn P et al.: Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Urology 70(2), 283-287 (2007).
15. D'Amico AV, Cote K, Loffredo M et al.: Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J. Clin. Oncol. 20(23), 4567-4573 (2002).
16. Stephenson AJ, Kattan MW, Eastham JA et al.: Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J. Clin. Oncol. 27(26), 4300-4305 (2009).
17. D'Amico AV, Chen MH, Roehl KA et al.: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N. Engl. J. Med. 351(2), 125-135 (2004).
18. Pinsky PF, Andriole G, Crawford ED et al.: Prostate-specific antigen velocity and prostate cancer Gleason grade and stage. Cancer 109(8), 1689-1695 (2007).
19. Ulmert D, Serio AM, O'Brien MF et al.: Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J. Clin. Oncol. 26(6), 835-841 (2008).
20. de Bono JS, Scher HI, Montgomery RB et al.: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14(19), 6302-6309 (2008).
21. Moreno JG, Miller MC, Gross S et al.: Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 65(4), 713-718 (2005).
22. Davis JW, Nakanishi H, Kumar VS et al.: Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J. Urol. 179(6), 2187-2191; discussion 2191 (2008).
23. Borre M, Offersen BV, Nerstrom B et al.: Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br. J. Cancer 78(7), 940-944 (1998).
24. Silberman MA, Partin AW, Veltri RW et al.: Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 79(4), 772-779 (1997).
25. Concato J, Jain D, Uchio E et al.: Molecular markers and death from prostate cancer. Ann. Intern. Med. 150(9), 595-603 (2009).
26. Halvorsen OJ, Haukaas S, Hoisaeter PA et al.: Independent prognostic importance of microvessel density in clinically localized prostate cancer. Anticancer Res. 20(5C), 3791-3799 (2000).
27. Revelos K, Petraki C, Scorilas A et al.: Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res. 27(5B), 3651-3660 (2007).
28. Bettencourt MC, Bauer JJ et al.: CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J. Urol. 160(2), 459-465 (1998).
29. Krupski T, Petroni GR, Frierson HF Jr et al.: Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate. Urology 55(5), 743-749 (2000).
30. Rubin MA, Buyyounouski M, Bagiella E et al.: Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology 53(3), 542-547 (1999).
31. Fleming C, Wasson JH, Albertsen PC et al.; Prostate Patient Outcomes Research Team: A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 269(20), 2650-2658 (1993).
32. Steineck G, Helgesen F, Adolfsson J et al.: Quality of life after radical prostatectomy or watchful waiting. N. Engl. J. Med. 347(11), 790-796 (2002).
33. Bill-Axelson A, Holmberg L, Filen F et al.: Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial. J. Natl Cancer Inst. 100(16), 1144-1154 (2008).
34. Lu-Yao GL, Albertsen PC, Moore DF et al.: Outcomes of localized prostate cancer following conservative management. JAMA 302(11), 1202-1209 (2009).
35. Shappley WV 3rd, Kenfield SA, Kasperzyk JL et al.: Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J. Clin. Oncol. 27(30), 4980-4985 (2009).
36. Klotz L, Zhang L, Lam A et al.: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J. Clin. Oncol. 28(1), 126-131 (2010).
37. Gupta A, Lotan Y, Ashfaq R et al.: Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur. Urol. 55(5), 1124-1133 (2009).
38. Vergis R, Corbishley CM, Norman AR et al.: Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol. 9(4), 342-351 (2008).